Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD025 PK in Hepatic Impairment
NCT04166942Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (4 arms), sponsored by Sanofi. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 3, Area under the concentration-time curve from time zero to the last measurable concentration at Day 3 and 5 more. Started Dec 2019; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04166942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166942.